SUNNYVALE, Calif., Sept. 13, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has appointed Mr. F. Randall Grimes, MBA as Director of Sponsored Research. Mr. Grimes will be focused on working with Amarantus' scientific team, Board of Advisors and outside collaborators to support the acquisition of non-dilutive funding from disease foundations, non-governmental and governmental organizations to advance Amarantus' pipeline.
"As we have now secured funding to allow the Company to operate well into 2014, we are in a good position to gain access to non-dilutive forms of funding to advance our pipeline in a number of key areas," said Gerald E. Commissiong, President & CEO of Amarantus. "Mr. Grimes' previous experience in gaining over $1.5 million in National Institutes of Health grants for LymPro will ultimately prove to be invaluable as we now have intimate access to historical knowledge that will guide our future sponsored research program in the LymPro program. Going forward for MANF, we intend to significantly leverage non-dilutive funding to support MANF product development, especially in secondary programs that will result from the reprioritizing process that we are currently conducting as a result of positive data in orphan indications that has begun to flow in from studies underway. We believe there is a significant appetite among certain disease foundations to support MANF development due to data that has already been generated, and given that we own the composition of matter patents and are moving forward in a product development program, we are in an excellent position to collaborate with the various researchers that have begun to publish on MANF. Having Mr. Grimes on in-house to coordinate the drafting and processing of grant applications will only serve to further help the Company leverage those resources."
Mr. F. Randall Grimes has more than 20 years of marketing, business development, financial and R&D leadership experience in early stage life science companies. He founded The Randall Group in 2001 to help small to medium-sized technology companies raise funds using state and federal competitive grants. He has garnered over $25 million in non-dilutive capital for clients and employers, including more than $1.5 million for LymPro Test development. Mr. Grimes has previously served as the Vice President of Technology Development at Provista Diagnostics, Inc., Vice President of Operations at RCP Diagnostics, Biomarker Technologies LLC and GW Medical Technologies LLC. Mr. Grimes has authored eight issued patents and has published articles in major technical and trade journals. He holds a B.S from University of Arizona in Material Sciences and Engineering and M.B.A from University of Michigan Business School with an emphasis in new product development, marketing and operations management.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV